Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
RIPK3 mediates pathogenesis of experimental ventilator-induced lung injury
Ilias I. Siempos, … , Kiichi Nakahira, Augustine M.K. Choi
Ilias I. Siempos, … , Kiichi Nakahira, Augustine M.K. Choi
Published May 3, 2018
Citation Information: JCI Insight. 2018;3(9):e97102. https://doi.org/10.1172/jci.insight.97102.
View: Text | PDF
Research Article Pulmonology

RIPK3 mediates pathogenesis of experimental ventilator-induced lung injury

  • Text
  • PDF
Abstract

In patients requiring ventilator support, mechanical ventilation (MV) may induce acute lung injury (ventilator-induced lung injury [VILI]). VILI is associated with substantial morbidity and mortality in mechanically ventilated patients with and without acute respiratory distress syndrome. At the cellular level, VILI induces necrotic cell death. However, the contribution of necroptosis, a programmed form of necrotic cell death regulated by receptor-interacting protein-3 kinase (RIPK3) and mixed-lineage kinase domain-like pseudokinase (MLKL), to the development of VILI remains unexplored. Here, we show that plasma levels of RIPK3, but not MLKL, were higher in patients with MV (i.e., those prone to VILI) than in patients without MV (i.e., those less likely to have VILI) in two large intensive care unit cohorts. In mice, RIPK3 deficiency, but not MLKL deficiency, ameliorated VILI. In both humans and mice, VILI was associated with impaired fatty acid oxidation (FAO), but in mice this association was not observed under conditions of RIPK3 deficiency. These findings suggest that FAO-dependent RIPK3 mediates pathogenesis of acute lung injury.

Authors

Ilias I. Siempos, Kevin C. Ma, Mitsuru Imamura, Rebecca M. Baron, Laura E. Fredenburgh, Jin-Won Huh, Jong-Seok Moon, Eli J. Finkelsztein, Daniel S. Jones, Michael Torres Lizardi, Edward J. Schenck, Stefan W. Ryter, Kiichi Nakahira, Augustine M.K. Choi

×

Figure 5

Defective fatty acid oxidation in critically ill patients.

Options: View larger image (or click on image) Download as PowerPoint
Defective fatty acid oxidation in critically ill patients.
(A) Calculati...
(A) Calculation of free carnitine to palmitoylcarnitine plus oleylcarnitine ratio [C0/(C16+C18), a screening test for deficiency of carnitine palmitoyl transferase (CPT1), which is a key enzyme in the fatty acid oxidation pathway] in plasma of patients with versus without acute respiratory distress syndrome (ARDS) (n = 86). (B) Critically ill patients, for whom both metabolomic data and plasma RIPK3 levels were available, were categorized into a “low RIPK3” group (i.e., those with plasma RIPK3 levels equal to or lower than median) and “high RIPK3” group (i.e., those with plasma RIPK3 levels higher than median) and were compared in terms of the ratio C0/(C16+C18) (n = 38). Red bars represent mean ± SEM. Statistical significance was calculated using Mann-Whitney U test.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts